STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Maze Therapeutics (MAZE) CEO’s family trusts sell 6,643 shares

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director and CEO Jason V. Coloma reported indirect open-market sales of company common stock by two family trusts associated with him. On June 1, 2026, the Coloma Family Trust sold 6,090 shares at a weighted average price of $26.1965 per share, leaving it with 344,897 shares. The Coloma 2021 Irrevocable Trust sold 553 shares at a weighted average price of $26.2412, leaving it with 27,970 shares. A footnote states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were scheduled in advance rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider Coloma Jason V
Role Chief Executive Officer
Sold 6,643 shs ($174K)
Type Security Shares Price Value
Sale Common Stock 6,090 $26.1965 $160K
Sale Common Stock 553 $26.2412 $15K
Holdings After Transaction: Common Stock — 344,897 shares (Indirect, Coloma Family Trust)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.545 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.50 per share, inclusive. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.
Total shares sold 6,643 shares Net shares sold across two open-market transactions on June 1, 2026
Family Trust sale 6,090 shares at $26.1965 Coloma Family Trust open-market sale of Maze common stock
Irrevocable Trust sale 553 shares at $26.2412 The Coloma 2021 Irrevocable Trust open-market sale
Family Trust holdings after sale 344,897 shares Maze common stock held by Coloma Family Trust post-transaction
Irrevocable Trust holdings after sale 27,970 shares Maze common stock held by The Coloma 2021 Irrevocable Trust post-transaction
Trading plan adoption date February 6, 2026 Date CEO adopted Rule 10b5-1 trading plan referenced in footnote
Price range Family Trust sales $26.00–$26.50 per share Multiple transactions underlying weighted average price (Family Trust)
Price range Irrevocable Trust sales $26.00–$26.545 per share Multiple transactions underlying weighted average price (Irrevocable Trust)
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Coloma Family Trust financial
"These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees."
Irrevocable Trust financial
"These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust")"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Coloma Jason V
(Last)(First)(Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026S(1)6,090D$26.1965(2)344,897IColoma Family Trust(3)
Common Stock06/01/2026S(1)553D$26.2412(4)27,970IThe Coloma 2021 Irrevocable Trust(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.545 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4.
3. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.
4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.50 per share, inclusive.
5. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.
/s/ Courtney Phillips, as attorney-in-fact06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Maze Therapeutics (MAZE) report in this Form 4?

Maze Therapeutics reported indirect open-market sales of common stock by family trusts associated with CEO Jason V. Coloma. Two trusts sold a combined 6,643 shares on June 1, 2026, while retaining substantial remaining holdings after the transactions.

How many Maze Therapeutics (MAZE) shares were sold and at what prices?

Two trusts associated with Maze’s CEO sold 6,643 shares in total. The Coloma Family Trust sold 6,090 shares at a weighted average of $26.1965, and the Coloma 2021 Irrevocable Trust sold 553 shares at a weighted average of $26.2412.

Were the Maze Therapeutics (MAZE) insider sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on February 6, 2026. Such plans pre-schedule trades, indicating the timing was set in advance rather than chosen opportunistically.

Are the Maze Therapeutics (MAZE) insider sales direct or indirect holdings of the CEO?

The reported shares are held indirectly through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust. Both trusts list Jason V. Coloma and his spouse as co-trustees, so the transactions are attributed to these entities rather than direct personal holdings.

What is the scale of the Maze Therapeutics (MAZE) insider selling activity in this filing?

The Form 4 shows 6,643 shares sold in total across two transactions. The filing’s transaction summary characterizes the activity as two open-market sales with a net-sell direction, while the trusts continue to hold significantly larger remaining positions.